Anemia, a common yet complex condition, can pose diagnostic challenges due to its multifactorial etiology. This guide aims to simplify the diagnostic approach to anemia, providing a comprehensive overview for healthcare professionals.
Understanding the classification of anemia is the first step towards an accurate diagnosis. Anemia can be broadly categorized into three groups based on mean corpuscular volume (MCV): microcytic, normocytic, and macrocytic. Each category has distinctive causes which must be identified to deliver appropriate treatment.
Initial diagnostic investigations for anemia generally include a complete blood count (CBC) and reticulocyte count. Further testing may involve serum iron studies, vitamin B12 and folate levels, hemoglobin electrophoresis, bone marrow examination, and genetic testing, depending on the clinical suspicion.
Microcytic anemia is often associated with iron deficiency, thalassemia, or anemia of chronic disease. Iron studies are crucial in differentiating these conditions. In iron deficiency anemia, serum iron and ferritin levels are typically low, while in thalassemia and anemia of chronic disease, they are usually normal or elevated.
Normocytic anemia could be a result of chronic disease, acute blood loss, or bone marrow dysfunction. Macrocytic anemia, on the other hand, is often linked to vitamin B12 or folate deficiency, medication side effects, or myelodysplastic syndromes. Specific tests can help identify the underlying cause.
Anemia is a complex condition with a wide range of causes. A systematic approach to its diagnosis, starting with a thorough understanding of its classification, followed by targeted investigations, can greatly aid in identifying the underlying cause and guiding treatment. This comprehensive guide serves as a practical tool for healthcare professionals navigating the complexities of anemia diagnosis.
1.
Prostate cancer detection with PET CT and PET MRI is comparable.
2.
Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy
3.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
4.
In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.
5.
Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma
1.
Innovative Intraoperative Therapies in Neurosurgical Oncology: Advancing Precision and Outcomes
2.
Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer
3.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
4.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
5.
The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Thromboprophylaxis In Medical Settings
2.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
4.
Efficient Management of First line ALK-rearranged NSCLC
5.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation